Clinical Practice Guideline: Management of Immune-related Adverse Events (Immune Checkpoint Inhibitors)
To aid in the recognition, evaluation and management of immune-related adverse effects in patients receiving immune checkpoint inhibitor immunotherapy.
•Immune checkpoint inhibitors (ICIs) are a type of immunotherapy that activate cytotoxic T-cells to treat cancer.
•Adverse effects are related to mechanism of action(immune activation leading to autoimmune damage) and can affect multiple different organs in the body.
•ICIs are used in many different hematologic/oncologic malignancies.